Lack of protective immunity against reinfection with hepatitis C virus - PubMed (original) (raw)
. 1992 Oct 2;258(5079):135-40.
doi: 10.1126/science.1279801.
Affiliations
- PMID: 1279801
- DOI: 10.1126/science.1279801
Lack of protective immunity against reinfection with hepatitis C virus
P Farci et al. Science. 1992.
Abstract
Some individuals infected with hepatitis C virus (HCV) experience multiple episodes of acute hepatitis. It is unclear whether these episodes are due to reinfection with HCV or to reactivation of the original virus infection. Markers of viral replication and host immunity were studied in five chimpanzees sequentially inoculated over a period of 3 years with different HCV strains of proven infectivity. Each rechallenge of a convalescent chimpanzee with the same or a different HCV strain resulted in the reappearance of viremia, which was due to infection with the subsequent challenge virus. The evidence indicates that HCV infection does not elicit protective immunity against reinfection with homologous or heterologous strains, which raises concerns for the development of effective vaccines against HCV.
Similar articles
- Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees.
Barth H, Rybczynska J, Patient R, Choi Y, Sapp RK, Baumert TF, Krawczynski K, Liang TJ. Barth H, et al. Hepatology. 2011 Oct;54(4):1135-48. doi: 10.1002/hep.24489. Epub 2011 Aug 11. Hepatology. 2011. PMID: 21674561 Free PMC article. - Immunity in hepatitis C infection.
Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspé G. Prince AM, et al. J Infect Dis. 1992 Mar;165(3):438-43. doi: 10.1093/infdis/165.3.438. J Infect Dis. 1992. PMID: 1538149 - Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization.
Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, Purcell RH. Farci P, et al. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7792-6. doi: 10.1073/pnas.91.16.7792. Proc Natl Acad Sci U S A. 1994. PMID: 7519785 Free PMC article. - Immunity in hepatitis C virus infection.
Prince AM. Prince AM. Vox Sang. 1994;67 Suppl 3:227-8. doi: 10.1111/j.1423-0410.1994.tb04581.x. Vox Sang. 1994. PMID: 7526553 Review. - Immunity elicited by hepatitis C virus.
Farci P, Orgiana G, Purcell RH. Farci P, et al. Clin Exp Rheumatol. 1995 Nov-Dec;13 Suppl 13:S9-12. Clin Exp Rheumatol. 1995. PMID: 8730469 Review.
Cited by
- ATAD1 inhibits hepatitis C virus infection by removing the viral TA-protein NS5B from mitochondria.
Zhou Q, Yang Y, Xu Z, Deng K, Zhang Z, Hao J, Li N, Wang Y, Wang Z, Chen H, Yang Y, Xiao F, Zhang X, Gao S, Li YP. Zhou Q, et al. EMBO Rep. 2023 Nov 6;24(11):e56614. doi: 10.15252/embr.202256614. Epub 2023 Oct 3. EMBO Rep. 2023. PMID: 37789674 Free PMC article. - Therapeutic strategies and promising vaccine for hepatitis C virus infection.
Adugna A. Adugna A. Immun Inflamm Dis. 2023 Aug;11(8):e977. doi: 10.1002/iid3.977. Immun Inflamm Dis. 2023. PMID: 37647422 Free PMC article. Review. - Therapy Implications of Hepatitis C Virus Genetic Diversity.
Martinez MA, Franco S. Martinez MA, et al. Viruses. 2020 Dec 29;13(1):41. doi: 10.3390/v13010041. Viruses. 2020. PMID: 33383891 Free PMC article. Review. - Impact of deranged B cell subsets distribution in the development of HCV-related cirrhosis and HCC in type two diabetes mellitus.
Abdelwahab FA, Hassanein KM, Hetta HF, Abdelmalek MO, Zahran AM, El-Badawy O. Abdelwahab FA, et al. Sci Rep. 2020 Nov 23;10(1):20383. doi: 10.1038/s41598-020-77416-0. Sci Rep. 2020. PMID: 33230233 Free PMC article. - Understanding, predicting and achieving liver transplant tolerance: from bench to bedside.
Thomson AW, Vionnet J, Sanchez-Fueyo A. Thomson AW, et al. Nat Rev Gastroenterol Hepatol. 2020 Dec;17(12):719-739. doi: 10.1038/s41575-020-0334-4. Epub 2020 Aug 5. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32759983 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical